Compare Gilead Sciences, Inc. (GILD) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Prospect Capital Corporation — how do they compare? Gilead Sciences, Inc. trades at $134.63 (market cap $163.51B), while Prospect Capital Corporation trades at $2.31 (market cap $1.14B). The key difference: Gilead Sciences, Inc. is far larger — about 143.4× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (22.03%). Which is the better fit depends on your goals.
| GILD | PSEC | |
|---|---|---|
Market Cap | $163.51B | $1.14B |
Sector | Health | Financials |
52-Week High | $155.80 | $3.47 |
52-Week Low | $108.22 | $2.15 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 22.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PSEC trades at $2.295, up 1.1% today, with a neutral technical signal and bearish moving averages. The stock shows a low P/B of 0.39 but negative revenue and net income in 2025. Recent earnings beats and consistent dividends highlight income potential, though financial performance remains volatile with a -495.94% net income margin. News includes a new investment in ShipOffers and the sale of Valley Electric.
Outlook is mixed: deep discount to NAV and high yield appeal to income seekers, but persistent financial deterioration and analyst skepticism pose risks. Upside depends on portfolio stability and NAV recovery, while downside risks include further dividend cuts and economic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
